China Healthcare Industry Will See A Strong 2010: Morgan Stanley
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Backed by Beijing's $124 billion investment in health system reforms over the next several years, the entire healthcare industry in China will see strong growth in 2010, say analysts from Morgan Stanley's research department
You may also be interested in...
Chinese Drug Companies Expected To Outperform Device Makers In 2010 - Morgan Stanley Valuation Overview
SHANGHAI - With a strong IPO performance for the Chinese healthcare sector in 2009, the total market cap for Chinese healthcare companies has reached $145 billion with 185 companies listed globally, according to the first China Healthcare Valuation Map, developed by Morgan Stanley research group in Hong Kong
Chinese Drug Companies Expected To Outperform Device Makers In 2010 - Morgan Stanley Valuation Overview
SHANGHAI - With a strong IPO performance for the Chinese healthcare sector in 2009, the total market cap for Chinese healthcare companies has reached $145 billion with 185 companies listed globally, according to the first China Healthcare Valuation Map, developed by Morgan Stanley research group in Hong Kong
Slow Growth And Tough Market Make China An Intriguing Puzzle For Indian Companies
MUMBAI - For large Indian drug companies, China has been a traditional and, to an extent, a dreaded rival in the business of pharmaceutical raw materials. Gargantuan Chinese factories that cropped up in the eighties almost killed scores of Indian bulk drug manufacturing units as every pricing strategy the Indian outfits could conceive of failed to beat the quotations offered by Chinese manufacturers to global brand name companies